The fusogenic (F) domain of human lmmunodeficiency virus (HIV) gp41 envelope (env) protein has sequence similarities to many viruses and mediates the fuston of HIV-infected cells. During a survey of the lmmunogenidty of HIV env peptldes in chimpanzees, we have observed that HIV peptide immunogenicity was dramatically altered by the NH2-terminal synthesis of the gp41 F domain to an otherwise immunogenic peptide. We compared two hybrid peptlde types comprised ofT helper (Th) and B cell epitopes ofHIV gp120 env protein for their immunogenicity in chimpanzees. The Th-B epitope hybrid peptldes contained the HIV gp120 Th cell determinant, T1 (amino acids [aa] 428-440) -synthesized NH2 terminal to gp120 V3 loop peptides, which contain B cell epitopes that induce anti-HIV-neutralizing antibodies (SP10IIIB [aa 303-321] and SP10IIIB [A] [aa 303-327]). The F-Th-B peptide contained the HIV gp41 F domain of HIVIIIB gp41 (aa 519-530) -synthesized NH2 termmal to the Th-B peptide. Whereas Th-B peptldes were potent immunogens for chimpanzee antibody and T cell-proliferative responses, the F-Th-B peptide induced lower anti-HIV gp120 T and B cell responses. Moreover, lmmumzation of chimpanzees with F-Th-B peptide but not Th-B peptides induced a significant decrease m peripheral blood T lymphocytes (mean decrease during immunization, 52%; p <0.02). Chimpanzees previously immunized with F-Th-B peptide did not respond well to immunization with Th-B peptide with T or B cell responses to HIV peptides, demonstrating that the F-Th-B peptide induced immune hyporesponsiveness to Th and B HIV gp120 env determinants. These observations raise the hypothesis that the HIV gp41 env F domain may be a biologically active immunoregulatory peptlde m wvo, and by an as yet uncharacterized mechamsm, promotes primate immune system hyporesponsiveness to otherwise immunogenic peptides.
Slllmmary
The fusogenic (F) domain of human lmmunodeficiency virus (HIV) gp41 envelope (env) protein has sequence similarities to many viruses and mediates the fuston of HIV-infected cells. During a survey of the lmmunogenidty of HIV env peptldes in chimpanzees, we have observed that HIV peptide immunogenicity was dramatically altered by the NH2-terminal synthesis of the gp41 F domain to an otherwise immunogenic peptide. We compared two hybrid peptlde types comprised ofT helper (Th) and B cell epitopes ofHIV gp120 env protein for their immunogenicity in chimpanzees. The Th-B epitope hybrid peptldes contained the HIV gp120 Th cell determinant, T1 (amino acids [aa] 428-440) -synthesized NH2 terminal to gp120 V3 loop peptides, which contain B cell epitopes that induce anti-HIV-neutralizing antibodies (SP10IIIB [aa 303-321] and SP10IIIB [A] [aa 303-327]). The F-Th-B peptide contained the HIV gp41 F domain of HIVIIIB gp41 (aa 519-530) -synthesized NH2 termmal to the Th-B peptide. Whereas Th-B peptldes were potent immunogens for chimpanzee antibody and T cell-proliferative responses, the F-Th-B peptide induced lower anti-HIV gp120 T and B cell responses. Moreover, lmmumzation of chimpanzees with F-Th-B peptide but not Th-B peptides induced a significant decrease m peripheral blood T lymphocytes (mean decrease during immunization, 52%; p <0.02). Chimpanzees previously immunized with F-Th-B peptide did not respond well to immunization with Th-B peptide with T or B cell responses to HIV peptides, demonstrating that the F-Th-B peptide induced immune hyporesponsiveness to Th and B HIV gp120 env determinants. These observations raise the hypothesis that the HIV gp41 env F domain may be a biologically active immunoregulatory peptlde m wvo, and by an as yet uncharacterized mechamsm, promotes primate immune system hyporesponsiveness to otherwise immunogenic peptides.
T o design immunogens that induced Th and B cell-neutralizing antibody responses against HIV, we have designed synthetic peptldes (Th-B) comprised of linear arrays of functional regions of the HIV envelope (env) 1 (1) (2) (3) . The T1 sequence ofHIV gp120 (amino acids [aa] 428-440) is part of a conformational determinant of the CD4 binding site (4), unpubhshed results), and induced MHC class I-restricted CTL in mice against H2D a target cells expressing native HIV gp120 (2) .
While the role for the HIV gp41 F domain in mediation of cytopathic effects of HIV is estabhshed, an tmmunoregulatory role for the F domain has not been described. In th~s study, we found that Th-B peptides were potent immunogens and induced high-meted serum antibody and PBMCproliferative responses to ~mmunizmg pept~de and to gp120 protein in chimpanzees. In contrast, the F-Th-B peptide that contained the HIV gp41 F domain did not reduce high levels of antipeptide or anti-gp120 T and B cell responses, but rather induced relative peripheral blood T lymphopema and ~mmune hyporesponsiveness to H1V gp120 env Th and B determinants.
Materials and Methods
Peptides Peptides used m the study are hsted m Table 1 Peptxde synthesis was performed using exther t-boc or f-moc chemistry with a peptide synthesxzer (A431; Apphed Blosystems, Inc., Foster Cxty, CA) Peptides were purified using HPLC, and the molecular weight was determmed by fast atom bombardment mass spectrometry (R. B. Van Breeman, North Carohna State Umvers~ty, Raleigh, NC) using a double-focusing mass spectrometer (HXIIOHF, Joel Ltd, Tokyo, Japan) For Th-B and F-Th-B peptxdes (Table 1) , expected molecular weight of F-Th-B peptide, F-T1-SP10IIIB(A), was 5,908, observed was 5,907; expected molecular weight of Th-B peptlde, T1-SP10IIIB, was 4,061, observed was 4,062, expected and observed molecular weight of Th-B pepude, T1-SPl0IIIB(A), was 4,749, and expected and observed molecular weight of Th-B peptide, T1-SP10MN(A), was 4,771 For the peptldes used m the study (Table 1 ) the pept~de arriounts are gross weights. The percent water by Karl F~sher test (Galbra~th Laboratories, Inc, Knoxwlle, TN) for each peptlde was F-T1-SPl0IIIB(A), 6%, T1-SPIOIIIB(A), 8%, T1-SP10IIIB, 6%, and T1-SP10MN(A), 8%.
Animals. Chimpanzees were housed at t~he New Mexico State
Universxty Primate Factlity (Alamorgordo, NM) and were studied usmg protocols approved by the U.S. Department of Health and Human Serwces and Natmnal Instxtutes of Health primate research comrmttees, and by the New Memco State Umverslty Ammal Utthzat~on Commxttee Chimpanzee nos. 884 (15 yr old) and 1028 (12 yr old) had the same sire, ammals 1045 (10 yr old) and 1070 (11 yr old) were unrelated to each other and to ammals 884 and 1028 Outbred goats were housed at the Duke Umverslty Ammal Facahties and studied using experimental protocols approved by the Duke Umverslty Ammal Use Committee Ammal care and study procedures followed American Assoc~atlon of Laboratory Ammal Care gmdehnes
Immumzat,ons For goats, 3 mg of pepnde was rejected intramuscularly m each gluteal regmn m CFA (first dose), and then IFA (subsequent doses). For anmumzatlon of chimpanzees, var3ang doses of peptldes were rejected intramuscularly m IFA m a total volume of 4 cm 3, with 1 cm 3 xnjected into right and left upper arms and thighs ELISAs. 2/~g of Th-B peptlde, T1-SP10IIIB, or rgp120IIIB (Rephgen Corp., Cambridge, MD) m CBC buffer (15 mM NazCO3, 35 mM NaHCO3, pH 9.6) was incubated overmght m each well of a 96-well flat-bottomed plate (3590; Costar, Cambridge, MA) Wells were blocked with CBC buffer supplemented with 3% BSA for at least 2 h and then washed three umes with PBS, 0 05% Tween 20 Primary antibody at various concentrations m serum diluent (95 ml PBS, 0.05% Tween 20, supplemented with 5 g BSA and 2 ml normal serum from same species as secondary antibody) was incubated for 90 mm at 20~ After washmg three times, alkahne phosphatase-conjugated secondary antibody was added to each well (60 mm at room temperature), and the plates were washed Substrate (1 mg/mlp-mtrophenyl phosphate, Sigma Chemical Co, St. Lores, MO) in 0 05 M CBC, 0 002 M MgCI2 was added to each well, and plates were developed (60 ram, 20~ m the dark and read at 405 nm on an ELISA reader (Anthros, Denley Instruments Co, Durham, NC). Endpomt ELISA antibody tlters were defined as the serum t~ter at which the experimental/control (E/C) OD value was >--3.0.
HIV Neutrahzation Assays
The ablhty of chimpanzee or goat serum antibodies to neutrahze HIV was determined m syncytmm mhlbmon assay and reverse transcnptase mhlbmon assay as previously described (1, 3) Sera were heat macuvated (30 mm, 56~ before each assay.
PBMC Isolation and In Vztro FH]Thymzdme Incorporation Assays.
Chimpanzee or goat PBMC were isolated by standard density centnfugatlon techniques (1, 12) . In vatro assays of [3H]thymldme mcorporation were performed as described (1, 13) For chimpanzee PBMC assays, m vitro cultures were performed usmg 10% normal chimpanzee serum Antigens used m PBMC prohferatlon were the Tlters are endpomt ELISA tlters (tlters at whtch E/C were ~3.0) against the Th-B pepude, T1-SPl0IIIB * Ammal 1028 dtd not receive the month 5 mjecuon due to a sterile abscess at the rejection rite All mjecuons m ammal 1028 after month 5 were m PBS alone * Ammal 1070 dld not receive the month 20 mamumzauon due to the presence of high levels of ann-HIV-neutrahzmg anubo&es For ammals 884 and 1028, unmumzauons at months 2-5 were with T1-SP10IIIB, and months 6, 7, 8, and 14 with T1-SPl0IIIB(A) For ammals 1045 and 1070, immumzanon at month 16 was with T1-SP10IIIB(A)
deleted from the immunogen, and remained low throughout the remainder of the immunization period (Table 2 ). In chimpanzee no. 884, antibody titers rose at month 7 to 1:204,800 after five immunizations with Th-B peptides. Continued immunization of animal 884 with high doses of Th-B peptide (30 rag/dose) resulted in no further increases in antibody titer (Table 2) . In contrast, antipeptide antibody levels were much lower during months 1-10 of Immunization of animals 1045 and 1070 with HIVIIIB F-Th-B peptide, with peak antibody levels against tmmunizing peptide of 1:25,600 and 1:12,800 at month 7 for animals 1028 and 1070, respectively (Table 2) . After a 6-mo rest for all four animals, animals 884 and 1028 were lmmtmized at month 14 with 6 mg of Th-B peptlde. In chimpanzee no. 884, boosting w~th Th-B peptide in IFA at month 14 resulted in rise in titer of anfipeptide antibody to 1:102,400, while boosting of animal 1028 with peptide in PBS alone led to no antibody rise ( Table 2) .
In contrast, animals 1045 and 1070 were immunized at month 14 with 1 mg ("o0.016 mg/kg) of F-Th-B to determme if the prior doses of F-Th-B peptide were excessive and induced high zone tolerance, and if smaller amounts of F-derivatized peptide would be more immunogenic. Immunization of both chimpanzee nos. 1045 and 1070 with 1 mg of F-Th-B peptide after a 6-too rest resulted in only minimal rises m serum titers of antipepude antibody to 1:800 (Table 2) To determine if chimpanzee nos. 1045 and 1070 were tolerant to Th-B peptides, both animals were immunized on month 16 with HIVIIIB Th-B peptide, T1-SP10IIIB(A). Both animals 1045 and 1070 responded minimally to boosting v0ath Th-B peptide with antipeptide antibody responses of 1.1,600 and 1:3,200, respectively, demonstrating that animals 1045 and 1070 were hyporesponsive at month 16 to Th-B HIV env epitopes ( Table 2) .
Immunization of Animals 1045 and 1070 with HIVMN Th-B
Peptide Induced High Levels of Antipeptide Antibodies. Using a previously described strategy of breaking B cell tolerance by immunization with an immunogen that is different from, but structurally related to, the tolerogen (14), we next lmmumzed animals 1045 and 1070 with the HIVMN Th-B peptide. The Th-B peptide from HIVMN contained the same Th (T1) gp120 sequence as the HIVIIIB Th-B peptide, but contained different B cell gp120 V3 B cell epitope sequences than those m the HIVIIIB Th-B peptide (Table 1) . After two immunizations with Th-B of HIVMN, beginning at month 17, both chimpanzee nos. 1045 and 1070 had prompt rises m titer of antibodies to HIVIIIB (Table 2 ) and to HIVMN Th-B peptide (not shown) to antibody levels that were higher than had previously been obtained during the prior 18 mo of study At month 20, endpoint ELISA titers to the HIVMN Th-B peptide were 1:102,400 for animal 1045 and 1:204,800 for ammal 1070.
Chimpanzee B Cell Antibody Responses to Recombinant
HIVIIIB gpl20 during the 20-too Immunization Course. Endpoint ELISA antibody tlters against recombinant HIVIIIB gp120 were determined for sera from months 4-7 and 16-20 to correlate peak antipeptide antibody levels with anu-gp120 HIV env anubody levels. We found that peak anti-gpl20 antibody levels in chimpanzee nos. 884 and 1028 during months 4-7 were both 1:25,600, whereas peak titers to gp120 m ammals 1045 and 1070 during the same period were 1:6,400 and 0, respectively. As with antipepude antibody levels, boosting after a 6-too rest with peptide in PBS in chimpanzee no. 1028 did not boost anti-gp120 antibodies.
Boosting with F-Th-B pepttde at month 14 and with HIVIII (Fig. 1, A and B) during months 1-8, F-Th-B peptide did not induce levels of [3H]thymldine incorporation >100,000 Acpm/106 cells during the same period (Fig. 1, C and D) . Immunizauon of ammals 1045 and 1070 with Th-B peptide at month 16 did not induce the presence of circulating PBMC capable of proliferating to Th-B peptide in vitro (Fig. 1, C  and D) Interestingly, Th-B peptides at months 14-18 boosted PBMC-proliferative responses in animal 1028, while antipeptide antibody responses in animal 1028 during this ume were not boosted ( Fig. 1 B and Table 1 ).
Next, [3H]thymidme mcorporauon of chimpanzee PBMC to either recombmant gp120IIIB or to natwe gp120IIIB was tested. Table 3 shows the peak [3H]thymidine incorporation of chimpanzee PBMC to HIVIIIB gp120 for each animal during months 1-13, and demonstrates that neither chimpanzee no. 1070 nor 1045 (recewmg F-Th-B peptide) had PBMC-proliferauve responses to gp120 of E/C >2 throughout the first 13 mo of study. In contrast, animals 884 and 1028 (receiving Th-B peptides) did have anu-gp120-proliferatwe responses dunng the same period (Table 3) .
To determine ff PBMC-proliferatlve responses to mitogenic or antigenic stimuli other than HIV immunogens were normal in the F-Th-B-lmmumzed chimpanzees over the 20 mo of study, we also measured PBMC-proliferafive responses to PHA (Fig. 2) and to Candida (Fig. 3) . While peak PHA PBMCproliferative responses were nearly identical in the four chimpanzees, Candida PBMC-proliferauve responses varied from animal to animal and from month to month. However, in animals 1045 and 1070, we found that Candida responses were intermittently present dunng the time of immunization with F-Th-B peptide at levels that were similar to levels present before the immunizations were begun (Fig. 3, C and D) . determined throughout the immunization period ( Fig. 4 and Table 4 ). Whereas preimmunization (before) and postimmunization (during) lymphocyte levels in animals 884 and 1028 were not significantly different (Table 4) , animal 1045 became relatively lymphopenic (p <0.001) during the course of immunization with F-Th-B peptide with the lymphocyte count of 650/mm 3 at week 12, compared with preimmunization levels of 2,815 and 2,597 lymphocytes/mm 3 in months 1 and 2, respectively (Fig. 4 C) . Whereas T cell levels significantly dropped an average of 59 and 44% in chimpanzee nos. 1045 (p >0.001) and 1070 (p ;>0.02), respectively, during the immunization period, T cell levels did not significantly change in animals 884 arid 1028 during the same time (p 2>0.1) ( Table 4) . B and NK cell levels dropped significantly in animal 1045, but did not change in animals 1070, 884, and 1028 (Table 4) . Taken together, these data demonstrated that immunization with the F-derivatized HIV env peptide induced decreases in absolute levels of circulating T cells in both animals 1045 and 1070, and in B and NK cell levels in animal 1045, whereas immunization of chimpanzee nos. 884 and 1028 with HIV Th-B env peptides lacking the F domain did not significantly affect circulating lymphocyte levels. ........................... Fig. 5) . We found that after the fourth immunization, both peptides were capable of inducing serum anti-HIVIIIB-neutralizing antibodies (Fig. 5) (Table 5) .
Characterization of PB Lymphocyte Subsets dunng
To determine why antibodies against HIVIIIB Th-B peptides did not neutralize HIVIIIB in vitro during the first 17 mo of immunization, sera from the early peak anti-HIVIIIB pepude antibody responses (month 6) were assayed for reactiwty to the individual epitopes of the Th-B peptides. We found that at the ttme of initial h~gh mers of antl-Th-B peptide responses, most of the antibody reactivity in sera from ammals 884 and 1028 was indeed directed to the primary "Before" samples were stuched over a 5-mo period before lmmumzatlon with peptldes, n = 5 for lymphocytes, n = 3 for T, B, and NK ceils "Dunng" samples were taken from months 2-14 of lmmumzatlon n = 11 for lymphocytes, T, B, and NK cells Unless noted, p values for percent change companng "before" values with "dunng" values were not s~gmficant, with p >0 05 using student's t test *p >0 001 *p >0OO5
Sp >0 02
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---Goat 102A, F-TI-SPIOIIIB(A) Figure 5 . HIV env hybrid syntheuc pepudes reduced anu-HIVneutrahzmg antlbo&es m goats Goat 102A was lmmumzed with 3 mg of the F-Th-B peptlde, F-TI-SP10IIIB(A), and goat 104A was lmmumzed with the HIVIIIB Th-B pepude, TI-SP10IIIB Immumzauons were m CFA (first dose) and IFA (doses 2-4) Neutrahzmg uters are ttters at which reverse transcnptase production was inh,blted by 390% amino actd sequence of the neutralizing V3 loop region defined by the peptide (TRKSIRIQRGPGR) ( Table 6 ). These data suggest that antibodies made by chimpanzee nos. 884 and 1028 at 7 mo after immunization with the HIVIIIB Th-B HIV env peptides did not recognize the appropnate secondary V3 loop structure(s) necessary for neutralizing HIVIIIB, although the animals did make antibody responses to the correct primary amino acid sequences of the neutralizing V3 B cell determinant of HIVIIIB gp120.
Discussion
In this paper we have shown that synthesis of the HIV env gp41 F domain NH2-termmal to synthetic pepudes containing Th and B cell epitopes of HIV gp120 confe;red on the resulting peptlde the ability to reduce immune hyporesponsiveness in chimpanzees to Th and B epitopes of HIV gp120 and to induce relative T cell lymphopenia These observations may have clinical relevance m two areas, the pathophysiology of ineffective anti-HIV host immune responses, and the treatment of pathologic ant~-HIV immune responses m HIV infection.
The pathogenesis of ineffective anti-HIV mamune responses in HIV-infected humans is thought to be multffactonal, and indudes induction of B and T cell defects m antigen responsweness by HIV, infection of CD4 + APC by HIV, and &-rect HIV-mduced T cell death (reviewed in reference 15). Data in the present study raise the posslbihty that the HIV gp41 F region may reduce immune hyporesponsiveness m HIVinfected hosts to certain domains of the HIV envelope. (23) • (23) - (23) - (22) - (24) 1070 • (92) - ( Immunization of chimpanzees with the F-Th-B peptide did not generally immunosuppress the animals, smce PBMC PHA and Candida responses remained mtact. However, in both animals immunized with F-Th-B (1045 and 1070), a relative T cell lymphopenia developed that was temporally related to immunization with the derivatized peptide ( Fig.  4 and Table 4 ). Thus, we cannot rule out the possibility that F-derivatized peptides induced a more general immunosuppressed state than specifc antigen hyporesponslveness. However, at present, the immune hyporesponsive state induced by F-Th-B peptide most closely resembled classic immune tolerance to specific antigen (14) . Immune hyporesponsiveness in animals 1045 and 1070 to HIV env determinants was transient, and was completely reversed by Immunization of animals 1045 and 1070 with the Th-B peptide of HIVMN.
Because the observation of F-Th-B peptide-induced hyporesponsiveness was made in only two chimpanzees, consideration should be given to causes of immune tolerance other than immunization w~th F-derivatized peptides. First, all four animals were studied three to four times before immunization and, as well, were studied monthly throughout the 20 mo of study. The immune hyporesponslveness seen in animals Immunized with fusion domain peptides was a consistent finding throughout the time of immunization, and was temporally related to immunization with F-derivatlzed peptides. Moreover, PHA and Candida responses were normal throughout the immunization ume, whxle hyporesponsiveness in animals 1070 and 1045 was limited to Th and B determmants on HIV gp120, suggesting specificity of hyporesponslveness in F peptide-immunized animals. Second, animals were examined thoroughly each month throughout the study and no intercurrent Illnesses occurred in animals 1045 and 1070 during the time of immune tolerance Induction. Third, all four of the chimpanzees in our study had previously been used in hepatitis A, B, and C trials at the National Institutes of Health and the Centers for Disease Control All of the animals in the present study were in similar hepatms trials, and all are chnically healthy now 10-15 yr after the trials. Periodic mild elevations m liver function tests were noted in both Th-B-and F-Th-B-injected animals throughout the study period, a phenomenon frequently seen m animals given general anesthesia. Thus, the careful momtoring of the animals in the study, the consistent findings of hyporesponsiveness during the first 16 mo of immunization only in animals tmmumzed with F-derivatized peptides, and the prelmmunization control studies all suggest the immune hyporesponsiveness seen in animals 1070 and 1045 to gp120 Th and B determinants was due to immunization with F-derlvatized peptides. However, given the small number of animals studied, we can not conclusively rule out other cofactors that might have contributed to our observations.
Data in the present study may also have relevance to the treatment of pathologic anti-HIV immune responses in HIV infection. One hypothesis to explain immune deficiency in AIDS suggests that the attack of pathologic anti-HIV immune responses of HIV-lnfected cells may lead to numerous manifestations of AIDS (reviewed m reference 15). For example, regions of the HIV env protein with sequence similarities to MHC class I and II molecules have been described (reviewed in reference 16). Recent data suggest that tissue damage m the lymphocytic pneumonia syndrome associated with HIV (17) and the skin rash associated with acute simian ,mmunodeficiency virus infection in rhesus monkeys (18) are due to antiretrovaral CD8 + CTL. Finally, immune-mediated destruction of thymic, bone marrow, and lymph node microenvlronments has been postulated to play an euologic role in end-stage immune dysfunction in AIDS (reviewed in references 15 and 19). Thus, for pathogenic anti-HIV immune responses, what would be needed to treat HIV infecuon and prevent the development of climcal AIDS would be the induction of specific tolerance to HIV antigens that are targets of pathologac anti-HIV immune responses. Whether the strategy of conjugation of the HIV gp41 F domain to HIV immunogens other than those studied would result in tolerance induction is not known.
The F domain of HIV gp41 has sequence homology to several viruses that mediate cell fusion (10) . The HIV F domain inserts obliquely into lipid membranes, and has been postulated to be an amphlpathic hydrophobic helix in the context of a lipid bilayer (20). The more hydrophoblc amino acids are proposed to be located on one side of the putative helix, with the fusion domam inserting in lipid membranes as a sided insertional helical structure at a 70 ~ angle to promote membrane fusion (20, 21). The observation that F-derivatlzed HIV env peptides induced immune hyporesponstveness in chimpanzees, but not m goats or mice (2) , suggests that the HIV F domain has specificity for interaction with primate vs. lower specaes immune cells, although at present, the explanation for F domain tolerance induction in primates remains unknown It is plausible that the F portion of gp41 m pepttde form can be biologically active. HIV gp41 F domain peptides can inhibit HIV-induced cell fusion (22), and can lyse liposomes and insert into planar lipid membranes (23) .
Finally, an interesting observation in this study was the lack of requirement for IFA for boostmg PBMC-proliferative responses, while being required for boost of antibody levels m animal 1028 (Table 1 and Fig. 1 ). One explanation for the selective induction of proliferative responses by Th-B peptides in PBS would be the reduction of Thl-like responses (Th for CTL) by peptides in PBS and the induction of Th2-1ike (Th for antibody production), as well as Thl-like, responses by peptides in IFA (24) . In this regard, we have previously shown anti-HIV CTL generation by HIV env peptides m PBS in mice (M. K. Hart and B. F. Haynes, unpubhshed results). It has been suggested by some investigators that antivlral T cell responses may be reqmred for protective anti-HIV immunity (reviewed in reference 15), while others have suggested that anti-HIV-neutrahzing antibody responses are sufficient for protection from HIV challenges (25, 26) .
Thus, the immune responses to peptides seen in this study, i.e., Induction of T and B cell anti-HIV responses with IFA, the selecuve boost of anti-HIV epitope PBMC-prohferative responses with peptide with no adjuvant, and immune hyporesponsiveness to HIV env epitopes with HIV gp41 F domain-derivatized pepude, prov,de several new ways to
